Trial
NCT00460317
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Amgen
Collaborators
Takeda
Condition
Non-Small Cell Lung Cancer
Intervention
AMG 706
Why stopped
Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-07